Search

Your search keyword '"Bortesi B"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Bortesi B" Remove constraint Author: "Bortesi B" Database OpenAIRE Remove constraint Database: OpenAIRE
23 results on '"Bortesi B"'

Search Results

1. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

2. ERCC 1/BRCA1 PROTEIN EXPRESSIONS AND ERCC1/XPD/XRCC1-3 GENE POLYMORPHISMS AS PREDICTOR FACTORS OF OUTCOME IN STAGE IIIB-IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED IN FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CISPLATIN

3. ERCC 1/BRCA1 protein expressions and ERCC1/XPD/XRCC1-3 gene polymorphisms as predictor factors of outcome in stage III-IV non-small cell lung cancer (NSCLC) patients treated in first-line chemotherapy with or without cisplatin

4. Usefulness of 18FDG-positron emission tomography for early prediction of response in non-small cell lung cancer (NSCLC) patients treated with erlotinib: results of a pilot study

5. Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report

6. Immunoglobulin g fragment c receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with Cetuximab-based therapy

8. LOSS OF HETEROZYGOSITY (LOH) IN OVARIAN CANCER

15. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

16. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy

17. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

18. EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinilb-resistant patient with both concomitant mutations

19. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

20. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study

21. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non-small cell lung cancer

22. A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes

23. Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study

Catalog

Books, media, physical & digital resources